Henry Schein, Inc. logo

Henry Schein, Inc. (HSIC)

Market Closed
15 Oct, 08:00 PM
NASDAQ (NGS) NASDAQ (NGS)
$
86. 99
+1.43
+1.6713%
Pre Market
$
88. 00
+1.01 +1.1611%
9.54B Market Cap
21.94 P/E Ratio
- Div Yield
963,206 Volume
4.54 Eps
$ 85.56
Previous Close
Add Transaction
Day Range
86.24 87.33
Year Range
62.05 92.18
Want to track HSIC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Is Henry Schein (HSIC) Stock Undervalued Right Now?

Is Henry Schein (HSIC) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 1 month ago
HSIC vs. SAUHY: Which Stock Is the Better Value Option?

HSIC vs. SAUHY: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Henry Schein (HSIC) and Straumann Holding AG (SAUHY). But which of these two stocks is more attractive to value investors?

Zacks | 1 month ago
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term

Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 month ago
Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?

Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?

Henry Schein's broader growth, recurring technology revenues and savings plan support its outlook, but leverage and execution risks remain key concerns.

Zacks | 1 month ago
HSIC Raises 2026 Outlook as Sales and Margin Momentum Accelerates

HSIC Raises 2026 Outlook as Sales and Margin Momentum Accelerates

Henry Schein's stronger Q2 sales and margins prompt a 2026 outlook hike, but second-half savings execution remains key to sustaining earnings momentum.

Zacks | 1 month ago
Henry Schein (HSIC) is a Top-Ranked Growth Stock: Should You Buy?

Henry Schein (HSIC) is a Top-Ranked Growth Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 2 months ago
Here's Why Henry Schein (HSIC) is a Strong Momentum Stock

Here's Why Henry Schein (HSIC) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 2 months ago
Should Value Investors Buy Henry Schein (HSIC) Stock?

Should Value Investors Buy Henry Schein (HSIC) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 2 months ago
HSIC or SAUHY: Which Is the Better Value Stock Right Now?

HSIC or SAUHY: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Henry Schein (HSIC) and Straumann Holding AG (SAUHY). But which of these two stocks presents investors with the better value opportunity right now?

Zacks | 2 months ago
Henry Schein, Inc. (HSIC) Hits Fresh High: Is There Still Room to Run?

Henry Schein, Inc. (HSIC) Hits Fresh High: Is There Still Room to Run?

Henry Schein (HSIC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks | 2 months ago
Henry Schein, Inc. (HSIC) Q2 2026 Earnings Call Transcript

Henry Schein, Inc. (HSIC) Q2 2026 Earnings Call Transcript

Henry Schein, Inc. (HSIC) Q2 2026 Earnings Call Transcript

Seekingalpha | 2 months ago
Henry Schein Q2 Earnings Call Highlights

Henry Schein Q2 Earnings Call Highlights

Henry Schein NASDAQ: HSIC reported higher second-quarter sales, operating margins and earnings, citing accelerating internal sales growth, market-share gains in dental merchandise and early benefits from its value-creation program. The company also raised its full-year sales and adjusted earnings guidance.

Marketbeat | 2 months ago
Loading...
Load More